BR9911067A - Uso de inibidores de receptores de alfa1beta1 integrina e inibidores tgf-beta1 no tratamento de doença renal - Google Patents
Uso de inibidores de receptores de alfa1beta1 integrina e inibidores tgf-beta1 no tratamento de doença renalInfo
- Publication number
- BR9911067A BR9911067A BR9911067-9A BR9911067A BR9911067A BR 9911067 A BR9911067 A BR 9911067A BR 9911067 A BR9911067 A BR 9911067A BR 9911067 A BR9911067 A BR 9911067A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- tgf
- kidney disease
- beta1
- treatment
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 208000017169 kidney disease Diseases 0.000 title abstract 4
- 108091006082 receptor inhibitors Proteins 0.000 title abstract 2
- 108010055795 Integrin alpha1beta1 Proteins 0.000 title 1
- 102000006495 integrins Human genes 0.000 abstract 2
- 108010044426 integrins Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000008186 Collagen Human genes 0.000 abstract 1
- 108010035532 Collagen Proteins 0.000 abstract 1
- 102000004266 Collagen Type IV Human genes 0.000 abstract 1
- 108010042086 Collagen Type IV Proteins 0.000 abstract 1
- 206010018364 Glomerulonephritis Diseases 0.000 abstract 1
- 229920001436 collagen Polymers 0.000 abstract 1
- 210000000585 glomerular basement membrane Anatomy 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000010172 mouse model Methods 0.000 abstract 1
- 201000002793 renal fibrosis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K3/00—Materials not provided for elsewhere
- C09K3/18—Materials not provided for elsewhere for application to surfaces to minimize adherence of ice, mist or water thereto; Thawing or antifreeze materials for application to surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Combustion & Propulsion (AREA)
- Materials Engineering (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Patente de Invenção: <B>"USO DE INIBIDORES DE RECEPTORES DE ALFA1BETA1 INTEGRINA E INIBIDORES TGF-BETA1 NO TRATAMENTO DE DOENçA RENAL"<D>. A presente invenção fornece métodos para tratar (isto é, atrasar o início de, retardar a progressão de, e/ou reverter) distúrbios renais (por exemplo, glomerulonefrite renal e/ou fibrose renal). Certos destes métodos envolvem administrar um inibidor de receptor de <244>1<225>1 integrina opcionalmente em combinação com um inibidor de TGF-<225> 1. A presente invenção também fornece um modelo de camundongo para doença renal onde o camundongo não expressa uma composição de colágeno tipo IV normal na GBM (isto é, não incorpora cadeias de colágeno <244>3(IV), <244>(IV), e <244>5(IV) em sua membrana basal glomerular) e não expressa o receptor de <244>1<225>1 integrina.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8658798P | 1998-05-22 | 1998-05-22 | |
| US8876698A | 1998-06-02 | 1998-06-02 | |
| US15048598A | 1998-09-09 | 1998-09-09 | |
| PCT/US1999/011073 WO1999061040A2 (en) | 1998-05-22 | 1999-05-19 | USE OF α1β1 INTEGRIN RECEPTOR INHIBITORS AND TGF-β1 INHIBITORS IN THE TREATMENT OF KIDNEY DISEASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9911067A true BR9911067A (pt) | 2001-02-06 |
Family
ID=56289911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9911067-9A BR9911067A (pt) | 1998-05-22 | 1999-05-19 | Uso de inibidores de receptores de alfa1beta1 integrina e inibidores tgf-beta1 no tratamento de doença renal |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1079843B1 (pt) |
| JP (1) | JP2002516287A (pt) |
| CN (1) | CN1187084C (pt) |
| AT (1) | ATE359804T1 (pt) |
| BR (1) | BR9911067A (pt) |
| CA (1) | CA2329757C (pt) |
| CZ (1) | CZ296262B6 (pt) |
| DE (1) | DE69935853T2 (pt) |
| DK (1) | DK1079843T3 (pt) |
| EA (1) | EA004145B1 (pt) |
| EE (1) | EE04581B1 (pt) |
| ES (1) | ES2285841T3 (pt) |
| HU (1) | HUP0202048A3 (pt) |
| NO (1) | NO20005883L (pt) |
| NZ (1) | NZ508317A (pt) |
| PL (1) | PL345946A1 (pt) |
| PT (1) | PT1079843E (pt) |
| SG (1) | SG117434A1 (pt) |
| SI (1) | SI1079843T1 (pt) |
| TR (1) | TR200003432T2 (pt) |
| WO (1) | WO1999061040A2 (pt) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2557768T3 (es) | 1999-06-01 | 2016-01-28 | Biogen Ma Inc. | Un anticuerpo monoclonal bloqueante frente a VLA-1 y su uso para el tratamiento de trastornos inflamatorios |
| US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
| EP1214091B1 (en) * | 1999-09-14 | 2006-05-10 | Biogen Idec MA Inc. | Therapies for chronic renal failure using one or more integrin antagonists |
| WO2001066140A1 (en) * | 2000-03-09 | 2001-09-13 | Genzyme Corporation | Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| WO2002083854A2 (en) | 2001-04-13 | 2002-10-24 | Biogen, Inc. | Antibodies to vla-1 |
| BR0315054A (pt) * | 2002-11-01 | 2005-08-16 | Boys Town Nat Res Hospital | Ligando induzìvel para a integrina alfa 1 beta 1 e empregos |
| US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
| CN101494978A (zh) | 2006-05-25 | 2009-07-29 | 比奥根艾迪克Ma公司 | 治疗中风的方法 |
| GB0911888D0 (en) * | 2009-07-08 | 2009-08-19 | Oxford Biodynamics Ltd | Method of treating age related disorders |
| MX370199B (es) | 2012-02-16 | 2019-12-05 | Santarus Inc | Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a). |
| MX353562B (es) | 2012-04-25 | 2018-01-17 | Regulus Therapeutics Inc | Compuestos de microarn y metodos de modulacion de la actividad de mir-21. |
| UA116639C2 (uk) * | 2012-10-09 | 2018-04-25 | Рег'Юлес Терап'Ютікс Інк. | Способи лікування синдрому альпорта |
| CN104450726A (zh) * | 2013-09-17 | 2015-03-25 | 深圳华大基因科技有限公司 | Col4a5基因突变体及其应用 |
| CN104212806B (zh) * | 2014-07-21 | 2017-05-17 | 深圳华大基因股份有限公司 | Alport综合征新的突变致病基因及其编码蛋白和应用 |
| US20230374141A1 (en) * | 2020-10-05 | 2023-11-23 | Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital | Combination therapy for alport renal disease |
| CN112575074B (zh) * | 2020-10-09 | 2022-12-27 | 中山大学 | Nestin基因及蛋白在治疗器官纤维化中的应用 |
| WO2023085396A1 (ja) * | 2021-11-12 | 2023-05-19 | Ｕｂｅ株式会社 | アルポート症候群を治療または予防するための医薬組成物 |
| CN114698592B (zh) * | 2022-04-29 | 2022-11-04 | 中国医学科学院北京协和医院 | 一种干燥综合征肾损害小鼠模型的构建方法及其应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9519667D0 (en) * | 1995-09-27 | 1995-11-29 | Univ Manchester | Pharmaceutical composition |
-
1999
- 1999-05-19 PL PL99345946A patent/PL345946A1/xx unknown
- 1999-05-19 HU HU0202048A patent/HUP0202048A3/hu unknown
- 1999-05-19 WO PCT/US1999/011073 patent/WO1999061040A2/en active IP Right Grant
- 1999-05-19 SG SG200300701A patent/SG117434A1/en unknown
- 1999-05-19 EA EA200001092A patent/EA004145B1/ru not_active IP Right Cessation
- 1999-05-19 JP JP2000550500A patent/JP2002516287A/ja active Pending
- 1999-05-19 EE EEP200000685A patent/EE04581B1/xx not_active IP Right Cessation
- 1999-05-19 CZ CZ20004358A patent/CZ296262B6/cs not_active IP Right Cessation
- 1999-05-19 AT AT99923224T patent/ATE359804T1/de not_active IP Right Cessation
- 1999-05-19 PT PT99923224T patent/PT1079843E/pt unknown
- 1999-05-19 ES ES99923224T patent/ES2285841T3/es not_active Expired - Lifetime
- 1999-05-19 EP EP99923224A patent/EP1079843B1/en not_active Expired - Lifetime
- 1999-05-19 SI SI9930967T patent/SI1079843T1/sl unknown
- 1999-05-19 NZ NZ508317A patent/NZ508317A/en unknown
- 1999-05-19 CA CA2329757A patent/CA2329757C/en not_active Expired - Fee Related
- 1999-05-19 TR TR2000/03432T patent/TR200003432T2/xx unknown
- 1999-05-19 BR BR9911067-9A patent/BR9911067A/pt not_active IP Right Cessation
- 1999-05-19 CN CNB998090247A patent/CN1187084C/zh not_active Expired - Fee Related
- 1999-05-19 DK DK99923224T patent/DK1079843T3/da active
- 1999-05-19 DE DE69935853T patent/DE69935853T2/de not_active Expired - Lifetime
-
2000
- 2000-11-21 NO NO20005883A patent/NO20005883L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CZ20004358A3 (cs) | 2002-01-16 |
| CN1187084C (zh) | 2005-02-02 |
| DE69935853D1 (de) | 2007-05-31 |
| PT1079843E (pt) | 2007-06-26 |
| CN1310625A (zh) | 2001-08-29 |
| NO20005883L (no) | 2001-01-17 |
| WO1999061040A9 (en) | 2001-02-01 |
| DE69935853T2 (de) | 2008-01-10 |
| NO20005883D0 (no) | 2000-11-21 |
| CA2329757A1 (en) | 1999-12-02 |
| EP1079843B1 (en) | 2007-04-18 |
| SG117434A1 (en) | 2005-12-29 |
| EP1079843A2 (en) | 2001-03-07 |
| WO1999061040A2 (en) | 1999-12-02 |
| EE04581B1 (et) | 2006-02-15 |
| SI1079843T1 (sl) | 2007-10-31 |
| PL345946A1 (en) | 2002-01-14 |
| EE200000685A (et) | 2002-04-15 |
| CA2329757C (en) | 2013-11-19 |
| EA200001092A1 (ru) | 2001-06-25 |
| NZ508317A (en) | 2004-01-30 |
| EA004145B1 (ru) | 2004-02-26 |
| HUP0202048A2 (en) | 2002-10-28 |
| ES2285841T3 (es) | 2007-11-16 |
| CZ296262B6 (cs) | 2006-02-15 |
| JP2002516287A (ja) | 2002-06-04 |
| HUP0202048A3 (en) | 2006-11-28 |
| DK1079843T3 (da) | 2007-07-30 |
| TR200003432T2 (tr) | 2001-03-21 |
| ATE359804T1 (de) | 2007-05-15 |
| WO1999061040A3 (en) | 2000-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9911067A (pt) | Uso de inibidores de receptores de alfa1beta1 integrina e inibidores tgf-beta1 no tratamento de doença renal | |
| TW200510349A (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
| BR9913288A (pt) | Composição antioxidante compreendendo acetil l-carnitina e ácido alfa-lipóico | |
| BR0111913A (pt) | Análogos de gabapentina para distúrbios do sono | |
| BRPI0710485B1 (pt) | composições líquidas úteis no tratamento de doenças respiratórias | |
| EA200501601A1 (ru) | Соединения 1,2,4-оксадиазолбензойной кислоты и их применение | |
| BRPI0418029A (pt) | formulação de anticorpos cd40 e métodos | |
| BRPI0609711B8 (pt) | uso de uma solução aquosa com potencial redutivo oxidativo (orp) | |
| BR0014003A (pt) | Tratamento de combinação com compostos de diaril sufonil uréia e il-1ra | |
| AP9901471A0 (en) | Sulfonamides and derivatives thereof that modulate the activity of endothelin. | |
| BRPI0412893A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto | |
| BR0013219A (pt) | Métodos de tratamento ou inibição de pólipos de cólon, de tratamento ou inibição de câncer colorretal, uso de uma combinação de nsaid e de um inibidor de egfr quinase, composição farmacêutica, e, produto | |
| HUP0004025A2 (hu) | Viselkedési zavarok kezelése norepinefrin-újrafelvétel inhibitorokkal | |
| BRPI0612840A8 (pt) | Composição de ração para prevenir ou tratar doença renal, métodos para prevenir ou tratar doença renal e para produzir uma composição de ração, kit, e, meio para comunicar informação ou instruções | |
| BR0312947A (pt) | terapias para insuficiência renal empregando-se interferon-beta | |
| ATE231837T1 (de) | Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung | |
| BR0309095A (pt) | Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica | |
| BR9608835A (pt) | Processo para reduzir a hiperglicemia e estabilizar o nìvel de glicose no soro em humanos, tripicolinato crÈmico sintético em forma de dosagem unitária, e, uso do mesmo. | |
| BR0317573A (pt) | Agentes de receptores de linfotoxina beta em combinação com agentes quimioterapêuticos | |
| BRPI0415896A (pt) | combinações compreendendo um inibidor de hsp90 e um inibidor de fosfodiesterase para tratamento ou prevenção de neoplasia | |
| PT1390371E (pt) | Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores | |
| BR9909872A (pt) | uso de dexmedetomidina para uma unidade de sedação de proteção intensiva | |
| BR0108344A (pt) | Modulação de formação óssea | |
| BR9910678A (pt) | Composto, composição farmacêutica, método para traramento ou prevenção de uma doença inflamatória, método para tratamento de uma condição ou uma doença mediada por mmps, tnf, agrecanase, ou um composto dos mesmos, em um mamìfero, método de redução de nìveis de tnf em pacientes, sem a inibição de mmps, método para tratamento de uma condição ou uma doença e uso de um novo composto | |
| BR0214798A (pt) | Uso de anastrozol ou um sal farmaceuticamente aceitável do mesmo, e, métodos para reduzir a taxa de recorrência de câncer e a taxa de um novo tumor primário contralateral em uma mulher pós-menopausa tendo câncer de mama em estado inicial |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: O PRESENTE PEDIDO APRESENTA QUADRO REIVINDICATORIO COMPOSTO POR 36 REIVINDICACOES. NO ENTANTO, NO MOMENTO DO PEDIDO DE EXAME, FOI FEITA RETRIBUICAO RELATIVA A 9 REIVINDICACOES. PORTANTO, SOLICITA-SE QUE SEJA SANADA TAL IRREGULARIDADE PARA QUE SE DE PROSSEGUIMENTO AO EXAME TECNICO. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A E 12A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2135 DE 06/12/2011. |